liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden, Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Sørbye, H., Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Department of Oncology, University Hospital, Tromsö, Norway.
Byström, P., Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2008 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 19, no 5, 909-914 p.Article in journal (Refereed) Published
Abstract [en]

Background: To compare irinotecan with the Nordic 5-fluorouracil (5-FU) and folinic acid (FA) bolus schedule [irinotecan 180 mg/m2 on day 1, 5-FU 500 mg/m2 and FA 60 mg/m2 on day 1 and 2 (FLIRI)] or the Lv5FU2 schedule [irinotecan 180 mg/m2 on day 1, FA 200 mg/m2, 5-FU bolus 400 mg/m2 and infused 5-FU 600 mg/m2 on day 1 and 2 (Lv5FU2-IRI)] due to uncertainties about how to administrate 5-FU with irinotecan. Patients and methods: Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI. Primary end point was progression-free survival (PFS). Results: Patient characteristics were well balanced. PFS did not differ between groups (median 9 months, P = 0.22). Overall survival (OS) was also similar (median 19 months, P = 0.9). Fewer objective responses were seen in the FLIRI group (35% versus 49%, P = 0.001) but the metastatic resection rate did not differ (4% versus 6%, P = 0.3). Grade 3/4 neutropenia (11% versus 5%, P = 0.01) and grade 2 alopecia (18% versus 9%, P = 0.002) were more common in the FLIRI group. The 60-day mortality was 2.4% versus 2.1%. Conclusions: Irinotecan with the bolus Nordic schedule (FLIRI) is a convenient treatment with PFS and OS comparable to irinotecan with the Lv5FU2 schedule. Neutropenia and alopecia are more prevalent, but both regimens are equally well tolerated. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Place, publisher, year, edition, pages
2008. Vol. 19, no 5, 909-914 p.
Keyword [en]
5-fluorouracil, Chemotherapy, Colorectal cancer, Irinotecan, Randomized trial
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-46244DOI: 10.1093/annonc/mdm588OAI: diva2:267140
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2013-11-21

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Albertsson, M.Starkhammar, Hans
By organisation
Faculty of Health SciencesOncologyDepartment of Oncology UHL
In the same journal
Annals of Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 21 hits
ReferencesLink to record
Permanent link

Direct link